https://www.jls.fund/contact https://www.jls.fund https://www.jls.fund/portfolio https://www.jls.fund/success https://www.jls.fund/news-and-insights https://www.jls.fund/leonards-corner https://www.jls.fund/events https://www.jls.fund/team https://www.jls.fund/invest-with-us https://www.jls.fund/past-updates-archive https://www.jls.fund/this-week-in-psychedelics/a-psychedelic-pioneer-passes-away https://www.jls.fund/this-week-in-psychedelics/aaron-rodgers-ayahuasca-moran-stanley-psychedelics-microdosing https://www.jls.fund/this-week-in-psychedelics/abbvie-pharmaceuticals-and-aliada-therapeutics-gilgamesh-silopharma-mindbio https://www.jls.fund/this-week-in-psychedelics/activists-seek-to-expand-psychedelic-decriminalization-in-oakland https://www.jls.fund/this-week-in-psychedelics/ai-child-language-autism-heart-disease-autism-brain-inflammation-clearmind- https://www.jls.fund/this-week-in-psychedelics/alamar-biosciences-aspen-neuroscience-duke-health-alzheimers https://www.jls.fund/this-week-in-psychedelics/algernon-completes-dosing-the-first-cohort-in-its-phase-1-clinical-study-arizona-psilocybin-mushrooms-science-news https://www.jls.fund/this-week-in-psychedelics/algernon-neuroscience-doses-the-first-subjects-in-its-dmt-trial https://www.jls.fund/this-week-in-psychedelics/alto-neuroscience-fda-clearmind-medicine-cmnd-100 https://www.jls.fund/this-week-in-psychedelics/alzheimers-bridgebio-kentucky-40hz-light-sound-psychedelics https://www.jls.fund/this-week-in-psychedelics/alzheimers-mice-brains-peruvians-psychedelic-beer https://www.jls.fund/this-week-in-psychedelics/arizona-medical-potential-psilocybin-mushrooms-ohio-state-us-drug-enforcement-agency-oregon-health-authority https://www.jls.fund/this-week-in-psychedelics/aspen-neuroscience-orbimed-arch-venture-partners-gilead-clearmind-university-yale-school-of-psychiatry-voxelite https://www.jls.fund/this-week-in-psychedelics/atai-beckley-vanda-pharmaceuticals-hetlioz-fda-brainsight-deep-transcranial-magnetic-stimulation https://www.jls.fund/this-week-in-psychedelics/atai-life-sciences-and-beckley-psytech-seek-further-fda-approval-after-positive-results-from-depression-treatment-study https://www.jls.fund/this-week-in-psychedelics/atai-life-sciences-beckley-psytech-alcohol-use-disorder-mindbio https://www.jls.fund/this-week-in-psychedelics/atai-life-sciences-beckley-psytech-massachusetts-mental-health-options-cpt-code https://www.jls.fund/this-week-in-psychedelics/atai-lifescience-beckley-psytech-columbia-university-dr-alan-cohen-dr-mumesh-kumar https://www.jls.fund/this-week-in-psychedelics/avesta-ketamine-department-of-veterans-affairs-clearmind-maryland-house-the-house-health-and-government-operations-committee https://www.jls.fund/this-week-in-psychedelics/awakn-life-sciences-granted-fast-track-for-ketamine-assisted-therapy-for-alcohol-use-disorder-seelos-therapeutics-sb1454-hawaii https://www.jls.fund/this-week-in-psychedelics/awakn-life-sciences-mdma-oral-tablets-algernon-dmt-beckley-foundation-meditation https://www.jls.fund/this-week-in-psychedelics/awakn-life-sciences-portuguese-partner-hawaii-psychedelics-ukraine-psychedelic-research-association https://www.jls.fund/this-week-in-psychedelics/awakn-life-sciences-receives-uk-state-funding-for-ketamine-therapy https://www.jls.fund/this-week-in-psychedelics/awakns-ketmaine-clinic-in-london-receives-regulatory-approval https://www.jls.fund/this-week-in-psychedelics/biotech-small-pharma-depression-psychedelics-cory-booker-rand-paul-controlled-substances-act-psilocybin https://www.jls.fund/this-week-in-psychedelics/blake-mycoskie-thoms-shoes-psychedelics-investment-grief-gul-dolen-ethan-nadelman-podcast https://www.jls.fund/this-week-in-psychedelics/brain-research-electromagnetic-fields-flow-emf-psychedelicare-mount-sinai-mdma https://www.jls.fund/this-week-in-psychedelics/buckley-psytech-buys-eleusis-therapeutics-limited-john-hopkins-university-psychedelics-cigarette-addiction https://www.jls.fund/this-week-in-psychedelics/calaa-health-fda-compass-pathways-comp460-elecsys-neurofilament-light-chain https://www.jls.fund/this-week-in-psychedelics/california-australia-assembly-public-safety-committee-scott-wiener-psychedelics-eating-disorders https://www.jls.fund/this-week-in-psychedelics/california-city-takes-steps-to-decriminalize-psychedelics https://www.jls.fund/this-week-in-psychedelics/california-psychedelics-ballot-initiative-eating-disorders-couples-doing-ketamine-and-mdma-to-save-relationship https://www.jls.fund/this-week-in-psychedelics/cambridge-university-press-psilocybin-depression-lucy-walker-of-night-and-light-the-story-of-iboga-and-ibogaine-amanda-fielding https://www.jls.fund/this-week-in-psychedelics/can-california-legislators-overcome-newsoms-veto-plus-atai-life-sciences-publishes-encouraging-progress-from-phase-1-study-missouri-hb-1830 https://www.jls.fund/this-week-in-psychedelics/can-micro-dosing-make-us-less-anxious-and-depressed https://www.jls.fund/this-week-in-psychedelics/can-psilocybin-protect-against-opioid-use-disorder https://www.jls.fund/this-week-in-psychedelics/can-psychedelics-cure-color-blindness-american-medical-association-current-procedural-terminology-code-cpt https://www.jls.fund/this-week-in-psychedelics/can-psychedelics-help-stop-the-opioid-epidemic https://www.jls.fund/this-week-in-psychedelics/canada-approves-numinus-wellness-application-to-complete-psychedelic-therapy https://www.jls.fund/this-week-in-psychedelics/canadian-health-care-provider-to-reimburse-psychedelic-therapies-missouri-to-research-ibogaine-as-a-treatment-for-opioid-addiction https://www.jls.fund/this-week-in-psychedelics/case-western-parkinsons-onward-medical-centre-hospitalier-denfinium-therapeutics https://www.jls.fund/this-week-in-psychedelics/cellares-corporation-smart-factory-cell-shuttle-solvonic-therapeutics-michael-j-fox-foundation https://www.jls.fund/this-week-in-psychedelics/clearmind-medicine-hadassah-medical-center-alcohol-use-disorder-lithium-alzheimers https://www.jls.fund/this-week-in-psychedelics/clinical-trial-for-possible-new-absence-epilepsy-treatment-mdma-used-in-a-johns-hopkins-clinical-trial-new-dementia-findings https://www.jls.fund/this-week-in-psychedelics/colorado-psychedelics-polis-psilocybin-depression https://www.jls.fund/this-week-in-psychedelics/compass-pathways-phase-3-helus-pharma-nature-medicine-alzheimers https://www.jls.fund/this-week-in-psychedelics/compass-pathways-presents-positive-results-on-psilocybin-therapy-as-depression-treatment https://www.jls.fund/this-week-in-psychedelics/compass-pathways-private-placement-red-light-holland-psilocybin-mdma-lsd https://www.jls.fund/this-week-in-psychedelics/could-psilocybin-be-the-secret-to-staying-young-how-this-psychedelic-compound-might-increase-the-lifespan-of-human-cells-and-slow-aging https://www.jls.fund/this-week-in-psychedelics/could-psychedelics-help-treat-als-north-carolina-clearmind-medicine-cmnd-100-breakthrough-therapies-advisory-board https://www.jls.fund/this-week-in-psychedelics/could-psychedelics-reduce-psychotic-symptoms-in-teens-plus-cybin-inc-gets-closer-to-first-fda-approved-psychedelic-therapeutic-for-mdd-ama-utah-mdma https://www.jls.fund/this-week-in-psychedelics/could-psychedelics-repair-consciousness-after-brain-trauma-washington-jesse-saloman-legalization https://www.jls.fund/this-week-in-psychedelics/could-this-drink-prevent-alzheimers-and-clearmind-medicine-initiates-new-clinical-trial-for-its-alcohol-use-disorder-treatment https://www.jls.fund/this-week-in-psychedelics/could-washington-be-the-next-state-to-legalize-certain-psychedelics-for-personal-use-glial-neurons-california https://www.jls.fund/this-week-in-psychedelics/current-procedural-terminology-cpt-psychedelic-drugs-defense-bill-massachusetts-for-mental-health-options https://www.jls.fund/this-week-in-psychedelics/cybin-acquires-small-pharma-beckley-psytech-treatment-resistant-depression-california-psychedelic-wellness-and-healing-initiative https://www.jls.fund/this-week-in-psychedelics/cybin-fluence-congress-department-of-defense-psychedelic-research-case-western-yale-harvard-psychiatrists-attitudes-towards-psychedelics https://www.jls.fund/this-week-in-psychedelics/cybin-inc-cyb003-psilocybin-missouri-military-veterans-suicide-mushrooms-colorado-ethnogenics https://www.jls.fund/this-week-in-psychedelics/cybin-inc-drug-depression-dmt-imperial-college-london-robert-garcia-earl-blumenauer-spending-bill https://www.jls.fund/this-week-in-psychedelics/cybin-inc-receives-permission-from-dea-to-begin-groundbreaking-psychedelic-study https://www.jls.fund/this-week-in-psychedelics/cybin-phase-3-paradigm-doug-drysdale-cyb003-trace-neuroscience-series-a-hbot-ptsd https://www.jls.fund/this-week-in-psychedelics/cybin-receives-fda-clearance-for-historic-psilocybin-clinical-trial https://www.jls.fund/this-week-in-psychedelics/cybins-data-demonstrates-remarkable-response-rate-tryptamine-advances-trial-georgia-progresses-bi-partisan-psychedelics-proposal https://www.jls.fund/this-week-in-psychedelics/dea-administrative-judge-hearing-psychedelic-ban-pharmala-optimi-health https://www.jls.fund/this-week-in-psychedelics/dea-quotas-psychedelic-research-berkley-decriminalize-lsd-vikings-beserkers-henbane https://www.jls.fund/this-week-in-psychedelics/dementia-cortec-neruo-genetech-active-bci https://www.jls.fund/this-week-in-psychedelics/diamond-therapeutics-alabama-psilocybin-demoralization-eureka-decriminalize-lsd-business-managers https://www.jls.fund/this-week-in-psychedelics/dmt-brain-oregon-production-license-psilocybin-colorado-department-regulatory-agencies https://www.jls.fund/this-week-in-psychedelics/doxycycline-antibotic-schizophrenia-virginia-tech-neurobiology-research-roche-manifold-bio https://www.jls.fund/this-week-in-psychedelics/drug-science-college-of-london-fda-mindstate-design-labs https://www.jls.fund/this-week-in-psychedelics/emotional-experiences-behavioral-trends-rna-gaming-addiction-teens-nature-communications-synaptic-connections- https://www.jls.fund/this-week-in-psychedelics/enthea-health-benefit-plan-reunion-neuroscience-re104-postpartum-depression-cpcr-psilocybin https://www.jls.fund/this-week-in-psychedelics/enveric-biosciences-takes-major-step-towards-submitting-new-drug-application-to-the-fda-how-ai-could-improve-neuroscience-studies https://www.jls.fund/this-week-in-psychedelics/epia-neuro-bci-operon-cotec-neuro https://www.jls.fund/this-week-in-psychedelics/epilepsygtx-biogen-stoke-therapeutics-dravet-zorevunersen https://www.jls.fund/this-week-in-psychedelics/epstein-barr-virus-mononucleosis-teva-canada-somato-cognitive-action-network https://www.jls.fund/this-week-in-psychedelics/eu-psychedelics-cybin-fda-cyb004-maine-laura-supica-david-boyer https://www.jls.fund/this-week-in-psychedelics/executive-order-clearpoint-neuro-navigation-system-health-canada https://www.jls.fund/this-week-in-psychedelics/fda-brain-computer-interface-precision-neuroscience-fda-mindmed-major-depressive-disorder-parkinsons https://www.jls.fund/this-week-in-psychedelics/fda-to-consider-mdma-assisted-therapy-as-a-treatment-for-ptsd-arizona-takes-first-step-towards-legalizing-psychedelic-mushrooms-mind-bio https://www.jls.fund/this-week-in-psychedelics/fda-to-review-a-psychedelic-drug-application-for-the-first-time-ever-could-our-industry-be-on-the-verge-of-a-historic-milestone https://www.jls.fund/this-week-in-psychedelics/federal-health-agency-acknowledges-the-potential-health-benefits-of-psilocybin-vermont-could-be-on-the-path-to-decriminalizing-shrooms https://www.jls.fund/this-week-in-psychedelics/filament-health-corp-fda-methamphetamine-california-psychedelics-university-of-ottawa https://www.jls.fund/this-week-in-psychedelics/filament-health-corporation-reset-pharma-otsuka-small-pharma-cybin-inc https://www.jls.fund/this-week-in-psychedelics/filament-health-psylocybin-anxiety-depression-algernon-pharmaceuticals-stroke-chronic-pain-ahmad-hammo https://www.jls.fund/this-week-in-psychedelics/filament-health-univeristy-of-london-alzheimers-nature-neuroscience-vr-infectious-disease https://www.jls.fund/this-week-in-psychedelics/finnish-medicines-agency-clairvoyant-therapeutics-fimea-fluence-hattie-wells-ethan-nadelmann https://www.jls.fund/this-week-in-psychedelics/fireflyvr-working-major-deals-with-unitedhealth-group-and-meta https://www.jls.fund/this-week-in-psychedelics/fluence-grows-revenue-by-124-maps-ptsd-mdma-cory-booker-rand-paul-congressional-psychedelics-advancing-clinical-treatments-caucus https://www.jls.fund/this-week-in-psychedelics/fontana-pharmacy-patoo-penn-state-cognitive-decline-washington-university-neurons https://www.jls.fund/this-week-in-psychedelics/gain-therapeutics-glusph-sanofi-syremis-parkinsons-alzheimers https://www.jls.fund/this-week-in-psychedelics/gavin-newsom-psilocybin-mdma-schedule-1-prescribe-portland-maine-psychedelics-compulsive-behavior https://www.jls.fund/this-week-in-psychedelics/genetech-roche-group https://www.jls.fund/this-week-in-psychedelics/germany-canada-therapsil-american-medical-association-diamond-therapeutics https://www.jls.fund/this-week-in-psychedelics/getting-high-goes-mainstream-how-boomers-and-the-media-are-embracing-psychedelics https://www.jls.fund/this-week-in-psychedelics/gh-research-compass-pathways-eli-lilly-ventyx-biosciences https://www.jls.fund/this-week-in-psychedelics/gilgamesh-johnson-and-johnson-abbvie-major-depressive-disorder-lsd-psilocybin https://www.jls.fund/this-week-in-psychedelics/gilgamesh-ketamine-ukraine-military-ibogaine-irvin-dana-beal https://www.jls.fund/this-week-in-psychedelics/gilgamesh-named-one-of-fierce-biotechs-fierce-15-fda-backpedals-in-a-major-win-for-psychedelic-advocates-atai-life-olympia-washington https://www.jls.fund/this-week-in-psychedelics/gilgamesh-next-generation-psychedelic-medicines-rand-corporation-george-w-bush-institute https://www.jls.fund/this-week-in-psychedelics/gilgamesh-on-track-for-clinical-trials https://www.jls.fund/this-week-in-psychedelics/gilgamesh-pharmaceuticals-abbvie-department-of-veteran-affairs-mdma-assisted-therapy-ai-sex-based-brain-patterns https://www.jls.fund/this-week-in-psychedelics/gilgamesh-receives-a-billion-dollar-commitment-from-abbvie https://www.jls.fund/this-week-in-psychedelics/gladstone-institute-parkinsons-disease-cybin-inc-cyb003 https://www.jls.fund/this-week-in-psychedelics/have-scientists-finally-discovered-the-source-of-spoken-language-plus-colorado-issues-first-psilocybin-licenses-to-businesses https://www.jls.fund/this-week-in-psychedelics/hawaii-aloha-kyoto-university-revive-theapeutics-amyothropic-lateral-sclerosis https://www.jls.fund/this-week-in-psychedelics/hawaii-mdma-psilocybin-adrian-tam-australia-the-guardian-europe-pinsent-masons-european-pharmaceutical-review https://www.jls.fund/this-week-in-psychedelics/hawaii-to-study-psilocybin-mushrooms https://www.jls.fund/this-week-in-psychedelics/how-psychedelics-are-making-their-mark-on-modern-stories-culture https://www.jls.fund/this-week-in-psychedelics/how-psychedelics-can-help-athletes https://www.jls.fund/this-week-in-psychedelics/immunis-nevada-alternative-therapy-pilot-program-right-brain-bio-pharmather-holdings https://www.jls.fund/this-week-in-psychedelics/interest-in-microdosing-psychedelics-surges-amidst-reforms-ma-aims-for-a-november-ballot-initiative-after-legislative-stall-eeg-marks-100-years-shaping-neuroscience https://www.jls.fund/this-week-in-psychedelics/j-p-morgan-life-sciences-private-capital-dr-guarav-gupta-icannex-phase-2-psi-gad1-missouri-state https://www.jls.fund/this-week-in-psychedelics/jls-fluence-psilocybin-oregon-new-york-legalize-psychedelics-alberta https://www.jls.fund/this-week-in-psychedelics/john-hopkins-nicotine-treatment-xenon-pharmaceuticals-red-light-holland-filament https://www.jls.fund/this-week-in-psychedelics/johnson-and-johnson-intra-cellular-therapies-elon-musk-brain-computer-interface-neuralink-cybin-inc-segal-trials https://www.jls.fund/this-week-in-psychedelics/jordan-belfort-ibogaine-california-psychedelics-massachusetts-anosmia-microsmia https://www.jls.fund/this-week-in-psychedelics/kentucky-opioid-settlement-money-psychedelic-research-european-parliament-action-group-for-the-medical-use-of-psychedelics https://www.jls.fund/this-week-in-psychedelics/ketamine-fibromyalgia-silo-pharma-sp-26-nature-mental-health-scientists-university-of-turku-finland https://www.jls.fund/this-week-in-psychedelics/ketamine-shows-promise-as-treatment-for-alcohol-dependency https://www.jls.fund/this-week-in-psychedelics/lb-pharmaceuticals-ipo-lb-102-icobrain-icometrix-charles-zucker-ge-healthcare https://www.jls.fund/this-week-in-psychedelics/lund-university-alzheimers-china-adhd https://www.jls.fund/this-week-in-psychedelics/m-a-p-s-makes-progress-in-mdma-therapy-for-ptsd https://www.jls.fund/this-week-in-psychedelics/maryland-creates-fund-for-psychedelic-treatment-for-veterans-with-ptsd https://www.jls.fund/this-week-in-psychedelics/massachusetts-ballot-initiatives-psilocybin-work-business-therapeutic-potential-federal-health-officials https://www.jls.fund/this-week-in-psychedelics/massachusetts-bay-staters-for-natural-medicine-missouri-dana-farber-cancer-institute-hospice-psychedelics https://www.jls.fund/this-week-in-psychedelics/massachusetts-governor-mdma-military-veterans-house-lawmakers-congressional-hearing-awakn-life-sciences-corp https://www.jls.fund/this-week-in-psychedelics/massachusetts-psychedelics-mental-health-options-compass-pathways-national-defense-authorization-act https://www.jls.fund/this-week-in-psychedelics/mdma-dogs-ritalin-allen-institute-asceneuron-series-c-financing https://www.jls.fund/this-week-in-psychedelics/mdma-shows-promise-for-treating-ptsd https://www.jls.fund/this-week-in-psychedelics/mdma-transdermal-patch-revive-therapeutics-pharmatech-therapeutic-goods-administration https://www.jls.fund/this-week-in-psychedelics/microscopy-ozempic-wegovy-diabetes-alzheimers-clearmind-clinical-trial-john-hopkins-university-alcohol-use-disorder https://www.jls.fund/this-week-in-psychedelics/mindbio-therapeutics-atai-life-sciences-and-mindmed-provide-updates-on-their-historic-clinical-trials-and-drug-studies https://www.jls.fund/this-week-in-psychedelics/mindmed-lsd-clinical-trial-anxiety-psilocybin-alcoholism-jama-psychiatry-dea-hallucinogens https://www.jls.fund/this-week-in-psychedelics/minneapolis-decriminalizes-psychedelics-california-pushes-for-legalization-statewide-and-federally-in-2024-current-geriatrics-report https://www.jls.fund/this-week-in-psychedelics/minnesota-legislature-psychedelic-task-force-colorado-jared-polis-psychedelic-psilocybin-california-bill-58 https://www.jls.fund/this-week-in-psychedelics/minnesota-psychedelic-medicine-task-force-psilocybin-mdma-lsd-university-pittsburgh-cell-reports https://www.jls.fund/this-week-in-psychedelics/morgan-stanley-compass-pathways-category-5-horizons-conference-summit-on-breakthrough-therapies https://www.jls.fund/this-week-in-psychedelics/multiple-sclerosis-fda-american-ibogaine-hubbard-stanford-university-rna https://www.jls.fund/this-week-in-psychedelics/mydecine-innovations-signs-major-partnership-with-health-canada https://www.jls.fund/this-week-in-psychedelics/national-institutes-of-health-monica-bertagnolli-escitalopram-mindbio https://www.jls.fund/this-week-in-psychedelics/nature-dopamine-mice-paralyzed-man-drone-brain-computer-interface-x-chromosome-aging https://www.jls.fund/this-week-in-psychedelics/neurobiology-of-disease-parkinsons-atai-life-sciences-sad-city-of-st-georges-university-of-london-ai https://www.jls.fund/this-week-in-psychedelics/new-jersey-senate-therapeutic-psilocybin-pharmala-biotech-holdings-mdma-harvard-heroic-hearts-project https://www.jls.fund/this-week-in-psychedelics/new-study-shows-the-benefits-of-psychedelics-for-people-with-cancer https://www.jls.fund/this-week-in-psychedelics/new-york-legislature-considers-medical-psilocybin https://www.jls.fund/this-week-in-psychedelics/new-york-psilocybin-service-centers-legislation-amy-paulin-veteran-health-administration-psychedelic-medicine-integrated-project-team-aspen-psychedelic-symposium https://www.jls.fund/this-week-in-psychedelics/newamsterdam-pharmas-alzheimers-drug-passes-another-test-plus-how-genetic-variations-make-us-more-or-less-susceptible-to-our-environment https://www.jls.fund/this-week-in-psychedelics/nicholas-boldyga-massachusetts-psychedelic-reform-maps-body-dysmorphic-disorder https://www.jls.fund/this-week-in-psychedelics/nih-explores-the-therapeutic-potential-of-kratom https://www.jls.fund/this-week-in-psychedelics/novamind-ketamine-breaks-through-with-insurance-providers https://www.jls.fund/this-week-in-psychedelics/numinous-acquires-novamind-and-cybin-releases-promising-new-data https://www.jls.fund/this-week-in-psychedelics/oogle-co-founder-sergey-brin-is-putting-up-15-million-to-help-fund-biotech-startup-soneira-reunion-neuroscience-students-for-sensible-drug-policy-ssdp https://www.jls.fund/this-week-in-psychedelics/organoids-itay-beyond-heidelberg-university-death-switch-shionogi-apnimed https://www.jls.fund/this-week-in-psychedelics/otsuka-transcend-therapeutics-billion-anxiety-disorder-definium-therapeutics https://www.jls.fund/this-week-in-psychedelics/our-portfolio-company-psilera-makes-waves-in-tampa-bay-with-its-dementia-treatment-maine-psilocybin-journal-of-the-neurological-sciences https://www.jls.fund/this-week-in-psychedelics/paradromics-brain-computer-interface-connexus-bci-pittsburgh-school-of-medicine-cingulum-bundle-frontal-temporal-dementia-psilera- https://www.jls.fund/this-week-in-psychedelics/parkinsons-dogs-music-cognitive-decline https://www.jls.fund/this-week-in-psychedelics/pharmala-biotech-holdings-harvard-university-hospital-clinical-trial-fruit-fly-neuron-by-neuron-map https://www.jls.fund/this-week-in-psychedelics/pharmather-holdings-fda-ketamine-ketarx-case-western-spinal-cord-injury https://www.jls.fund/this-week-in-psychedelics/praxi-precision-clene-inc-swiss-biotech-vandria https://www.jls.fund/this-week-in-psychedelics/precision-neuroscience-pharmala-bnc2-discovery https://www.jls.fund/this-week-in-psychedelics/promising-data-from-mindbio-a-bipartisan-effort-to-provide-psilocybin-to-military-vets-american-medical-association-favors-decriminalization https://www.jls.fund/this-week-in-psychedelics/pronovo-spravato-johnson-and-johnson https://www.jls.fund/this-week-in-psychedelics/psilera-atai-life-sciences-chris-witowski-the-journal-of-neuroscience-nature-institute-of-science-and-technology-austria https://www.jls.fund/this-week-in-psychedelics/psilera-dementia-drug-flimanet-psilocybin-fda-health-canada-arizona-legalize https://www.jls.fund/this-week-in-psychedelics/psilera-optimi-health-no-objection-letter-national-institute-of-health-ucsd https://www.jls.fund/this-week-in-psychedelics/psilocybin-nature-communications-medical-microinstrument-inc-symani-robotic-surgical-system-nrx-pharmaceuticals https://www.jls.fund/this-week-in-psychedelics/psychedelic-reforms-gain-traction-across-the-country https://www.jls.fund/this-week-in-psychedelics/psychedelic-santa-clause-mindmed-faces-a-setback https://www.jls.fund/this-week-in-psychedelics/psychedelic-therapy-biden-administration-decriminalization https://www.jls.fund/this-week-in-psychedelics/psychedelics-breast-cancer-migraines-connecticut-mdma-psilocybin https://www.jls.fund/this-week-in-psychedelics/psychedelics-gavin-newsom-scott-weiner-california-medford-psychedelics-and-sexual-functioning-scientific-reports https://www.jls.fund/this-week-in-psychedelics/psychedelics-inspire-rare-moment-of-bipartisanship https://www.jls.fund/this-week-in-psychedelics/psychedelics-legislation-health-insurance-marijuana-defense-bill https://www.jls.fund/this-week-in-psychedelics/psychedelics-memory-john-hopkins-vr-transcendence-mit-mindset-pharma https://www.jls.fund/this-week-in-psychedelics/psychedelics-show-success-in-treating-both-fibromyalgia-and-lyme-disease-texas https://www.jls.fund/this-week-in-psychedelics/ptsd-postpartum-depression-mental-health-psychedelics-depressive-disorder-nolan-williams-huberman-lab-podcast https://www.jls.fund/this-week-in-psychedelics/reaching-across-the-aisle-to-promote-psychedelics https://www.jls.fund/this-week-in-psychedelics/reunion-breaktrhough-therapy-designation-fda-quralis-ataibeckley https://www.jls.fund/this-week-in-psychedelics/rhode-island-brandon-potter-legalize-psychedelics-algernon-pharmaceuticals-agn-neuro-bloomberg https://www.jls.fund/this-week-in-psychedelics/rhode-island-legalize-psilocybin-mushrooms-brandon-potter-oprah-winfrey-roland-griffiths https://www.jls.fund/this-week-in-psychedelics/roche-fda-alzheimers-elecsys-ptau181-bristol-myers-squibb-asl-ai-insitro https://www.jls.fund/this-week-in-psychedelics/sam-altman-merge-labs-novartis-epstein-barr-virus https://www.jls.fund/this-week-in-psychedelics/scisparc-clearmind-medicine-arizona-psilocybin-research-advisory-council-ukraine-psychedelics-dmytro-gurin https://www.jls.fund/this-week-in-psychedelics/shanghai-brain-computer-interface-tetraplegia-behavior-circadian-rhythms-adolescence-prenatal-infections https://www.jls.fund/this-week-in-psychedelics/silo-pharma-ptsd-new-york-state-schedule-1-controlled-substances-stem-cells-autism https://www.jls.fund/this-week-in-psychedelics/silo-pharma-spc14-alzheimers-nova-psychedelics-cory-booker https://www.jls.fund/this-week-in-psychedelics/soap-company-offers-psychedelic-treatment-as-part-of-its-healthcare-benefits https://www.jls.fund/this-week-in-psychedelics/stanford-and-emory-braingate-may-literally-give-a-voice-to-the-voiceless-reunion-neuroscience-announced-positive-topline-results https://www.jls.fund/this-week-in-psychedelics/teva-pharmaceuticals-ecopipam-emalex-biosciences-pacira-biosciences-helus-pharma-tara-mind https://www.jls.fund/this-week-in-psychedelics/the-center-for-psychedelics-health-and-research-launched-in-kingston-ontario-providence-care-hospital-massachusetts-psychedelic-decriminalization-and-legalization-measure https://www.jls.fund/this-week-in-psychedelics/the-dea-quotas-psychedelics-ibogaine-psilocybin-and-psilocyn-for-research-purposes-brigham-womens-hospital-neuron-lsd-anxiey https://www.jls.fund/this-week-in-psychedelics/the-rand-corporation-released-a-new-report-on-psychedelic-regulation-university-of-colorado-opens-a-psychedelic-research-center-a-study-on-extended-release-ketamine-tablets https://www.jls.fund/this-week-in-psychedelics/treat-california-filament-health-corp-health-canada-pex010-relmada-therapeutics https://www.jls.fund/this-week-in-psychedelics/tripp-flience-enthea-jama-psychiatry-silo-pharma https://www.jls.fund/this-week-in-psychedelics/tryp-therapeutics-announces-positive-results-for-treating-binge-eating-disorders https://www.jls.fund/this-week-in-psychedelics/tryp-therapeutics-binge-eating-and-bowel-syndrome-oregon-new-york-psychedelics-legalization https://www.jls.fund/this-week-in-psychedelics/tryptamine-therapeutics-begins-eating-disorder-treatment-trial-and-could-these-cancer-drugs-reduce-the-risk-of-alzheimers https://www.jls.fund/this-week-in-psychedelics/uc-berkeley-uc-san-francisco-brain-computer-interface-natural-soinding-speech-alzheimers-tau-protein-nature-mindstate-design-labs https://www.jls.fund/this-week-in-psychedelics/ultraprocessed-food-parkinson-joseph-sagol-neuroscience-center-alzheimers-dementia-texas-dallas-baylor-university-medical-center-ptsd https://www.jls.fund/this-week-in-psychedelics/us-city-moves-to-decriminazlie-psychedelics https://www.jls.fund/this-week-in-psychedelics/utah-forms-psychedelics-task-force https://www.jls.fund/this-week-in-psychedelics/veterans-affairs-providence-va-mindmed-innovation-passport https://www.jls.fund/this-week-in-psychedelics/virginia-on-the-verge-of-allowing-vets-to-use-psychedelics-gh-research-shows-huge-promise-with-new-drug-for-treatment-resistant-depression https://www.jls.fund/this-week-in-psychedelics/weve-got-updates-on-two-new-psychedelic-drugs-that-hope-to-treat-binge-eating-and-parkinsons-respectively https://www.jls.fund/this-week-in-psychedelics/zebrafish-love-ketamine-mindmed-begins-its-phase-3-voyage-and-the-dea-calls-for-increased-dmt-production